BackBristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company Net Tangible Assets

Latest net tangible assets for BRM.DE: $23B.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$23.40B
↑ 25.83% YoYΔ $4.80B vs prior year quarter

Peer trimmed avg / median

Loading

Bristol-Myers Squibb Company Net Tangible Assets History

Loading

Bristol-Myers Squibb Company vs. peers: Net Tangible Assets Comparison

Loading

Bristol-Myers Squibb Company Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bristol-Myers Squibb Company (BRM.DE) FAQ

The latest net tangible assets for BRM.DE is $23B as of September 2026. That compares with $19B in the prior-year period — up 25.8% year over year. Investors often review this figure alongside Bristol-Myers Squibb Company's historical trend and sector peers before judging valuation or financial health.

Over the past year, BRM.DE's net tangible assets moved from $19B to $23B — a 25.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bristol-Myers Squibb Company's operating scale or balance-sheet position.

A net tangible assets figure of $23B for BRM.DE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BRM.DE's net tangible assets ($23B), review year-over-year change from $19B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bristol-Myers Squibb Company's net tangible assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.